RECENT NEWS

The new Evident Slideview DX VS-M1 whole slide imaging system is a digital pathology solution that delivers high-quality slide images at high speed, helping pathologists make diagnoses quickly and efficiently. Built with renowned optics and advanced digital technology, the Slideview DX slide scanner is a complete digital pathology solution.

Mindpeak, a leading provider of artificial intelligence (AI) for pathology, and Proscia, a leading provider of digital and computational pathology solutions, have announced a partnership to broaden access to improved diagnosis for cancer patients.Through the collaboration, the companies lay the foundation for delivering tightly integrated AI-powered workflows that enable pathologists to provide more efficient, informed, and reproducible clinical decisions.

Yourgene Health, a leading international molecular diagnostics group, has presented data demonstrating that prolonged storage of blood in EDTA tubes is compatible with non-invasive prenatal testing (NIPT) when using size selection to enrich the fetal fraction.

The Sussex Pathology Network has chosen Clinisys for a laboratory information management system (LIMS) that will help its laboratories to collaborate, building on the supportive relationship that developed during the COVID-19 pandemic. A single, hosted instance of WinPath Enterprise will replace the existing four live LIMS systems in use at the three trusts and seven laboratories within the network, of which two are at the end of their life.

​H.E.L Group, a global developer and manufacturer of innovative laboratory tools for process optimisation, safety, and scale-up, today announced it will relocate its Greater London global headquarters from Borehamwood to Hemel Hempstead, over summer 2023. Overseen by interim Operational Director, Damian Slater, the move to new purpose-designed facilities supports the company’s continued expansion and plans for future growth.

This week The Royal College of Pathologists is celebrating National Pathology Week (NPW) - its annual celebration of pathology, highlighting the important contribution pathologists make to healthcare.

The next in the series of POCT events hosted by Thornhill Healthcare has been announced for London on 23 August, taking place at The Royal College of Pathologists in Aldgate.

Aiosyn, a software company that develops AI-powered pathology solutions, has announced the latest advancement in its automated quality control (QC) algorithm. Aiosyn’s QC solution, AiosynQC, is now fully compatible with immunohistochemistry (IHC) slides, in addition to haematoxylin and eosin (H&E) slides.

ProciseDx has announced that it is being acquired by Biosynex, a French diagnostics company that specialises in point-of-care testing. With the support of the Biosynex Group, ProciseDx expects to commercialise the first FDA-approved infliximab and adalimumab drug monitoring tests later this year.

The Lab Awards, to be presented at the Lab Innovations show held in November, are back and bigger than ever at this year’s show, where winners will be crowned in categories such as sustainability, collaboration and innovation.

Digital pathology and clinical AI firm Paige has launched the enhanced Paige Breast Suite, a complete set of products designed to empower pathologists in their diagnosis of breast cancer, reduce the subjectivity and tedium of manual diagnosis, and increase diagnostic efficiency and confidence.

Oxford Nanopore Technologies the company delivering a new generation of nanopore-based molecular sensing technology, and Geneyx, an AI platform for human genetic analysis and interpretation, are aiming to team up to develop the first scalable software solution for the end-to-end analysis and clinical reporting of nanopore sequencing data.

Nearly three-quarters of life sciences organisations surveyed have invested in digital pathology to advance drug research and development, according to new research commissioned by Proscia. Over half of these organisations (53%) still centre their operations around legacy software systems primarily for basic image viewing despite growing adoption of artificial intelligence (AI) to accelerate the introduction of breakthrough therapeutics.

A new Biothreats Radar capable of scanning biological risks that pose a threat to the public will be key to the UK’s fight and preparation for future pandemics, the Government has announced. It’s part of a new Biological Security Strategy to defend the UK from infectious disease outbreaks, antimicrobial resistance, and biological incidents and attacks.

Scientists from across the UK are hoping to learn how they can better predict leukaemia occurrence, as well as develop improved drug screening pathways to treat the disease, through a major funding boost worth £12 million.

BIOHIT HealthCare will be launching its GastroPanel Quick Test at BSG LIVE’23, which will take place from 19-22 June at the Arena and Conference Centre (ACC) Liverpool. This annual meeting provides the ideal opportunity to share this innovation with colleagues in the gastroenterology and hepatology community, as they come together to discuss the latest advances in the field.

GrapheneDx, General Graphene Corporation and Sapphiros have announced a strategic partnership to industrialise graphene-based biosensors for medical devices used to diagnose a variety of diseases at the point of care and in consumer settings.

Revvity has announced the launch of its Signals Research Suite, a unified, cloud-native software-as-a-service (SaaS) platform that drives scientific collaboration across R&D disciplines from drug discovery to specialty chemicals material development.

Roche has announced that the HPV test for use on the cobas 6800/8800 systems has been awarded World Health Organization (WHO) prequalification. WHO prequalification expands the availability of this critical HPV screening tool in countries that rely on the global organisation’s list in making purchasing and implementation decisions.

Axol Bioscience, a leading pluripotent stem cell technology provider for drug discovery, has signed an exclusive agreement with StrataStem to access and commercialise its extensive collection of Alzheimer’s disease (AD) patient samples.